Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
Want to see GRDN full AI Analyst Report?
Top Page
Guardian Pharmacy Services, Inc. Class A
(NYSE:GRDN)
Select Model
Select Model
Rating:68Neutral
Price Target:
$39.00
▲(3.89% Upside)
Action:Reiterated
Date:05/10/26
The score is driven primarily by improved financial performance (rapid growth, profitability rebound, strong balance sheet, positive free cash flow). Offsetting factors include a demanding valuation and mixed near-term technical momentum, while the latest earnings call was net positive but highlighted IRA-related pricing and working-capital volatility plus ongoing margin/cost headwinds.
Positive Factors
Very low leverage / stronger balance sheet
Debt-to-equity falling to ~0.03x TTM and equity expansion create durable financial flexibility. Low leverage reduces refinancing and solvency risk, supports M&A/greenfield spending, and provides a buffer against reimbursement or working-capital shocks over the next several quarters.
Negative Factors
Thin and volatile margins
Low TTM net and EBITDA margins leave earnings and cash flow vulnerable to modest cost increases or reimbursement changes. Historical swings (loss in 2024 then rebound) indicate persistent profitability volatility that could constrain sustained margin expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / stronger balance sheet
Debt-to-equity falling to ~0.03x TTM and equity expansion create durable financial flexibility. Low leverage reduces refinancing and solvency risk, supports M&A/greenfield spending, and provides a buffer against reimbursement or working-capital shocks over the next several quarters.
Read all positive factors
Guardian Pharmacy Services, Inc. Class A (GRDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.38B
Dividend YieldN/A
Average Volume (3M)348.83K
Price to Earnings (P/E)44.8
Beta (1Y)0.56
Revenue Growth13.54%
EPS GrowthN/A
CountryUS
Employees3,400
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.85
Shares Outstanding49,781,180
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit7.73
Enterprise Value/Ebitda23.19
Forecast
1Y Price Target
$43.00Price Target Upside14.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.23
Revenue Forecast (FY)$1.41B
Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model
Company Description
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing...
Guardian Pharmacy Services, Inc. Class A Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call conveyed a positive operational and financial outturn for Q1 2026: the company successfully navigated major IRA-driven disruption, delivered revenue resilience, strong gross profit and adjusted EBITDA growth, and raised adjusted EBITDA guidance. Key risks remain, including a severe (~60%) branded pricing decline caused by the IRA, temporary working capital and payment-timing stresses, margin pressure from recent acquisitions (~80 bps drag), and potential cost headwinds from fuel and labor. Management emphasized scale advantages, proactive payor negotiations, and confidence in normalization of working capital, while noting that certain quarter-specific benefits are non-recurring. On balance, highlights demonstrating execution and financial strength outweigh the lowlights tied mainly to one-time disruptions and ongoing cost/legislative uncertainty.Positive Updates
Revenue Resilience Despite IRA Impact
Reported revenue of $336.6 million for Q1 2026, up 2% year-over-year. Management estimates that absent the government-mandated IRA price declines revenues would have grown by low double digits year-over-year.
Negative Updates
Severe IRA-Branded Pricing Decline
Approximately 60% decline in pricing across the company's branded drug mix impacted by the IRA, creating significant industry headwinds that required proactive mitigation and renegotiation with payors.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Resilience Despite IRA Impact
Reported revenue of $336.6 million for Q1 2026, up 2% year-over-year. Management estimates that absent the government-mandated IRA price declines revenues would have grown by low double digits year-over-year.
Read all positive updates
Company Guidance
Management kept revenue guidance unchanged at $1.40–$1.42 billion for FY2026 and raised full‑year adjusted EBITDA to $123–$127 million (from $120–$124 million) to reflect a $3 million discrete benefit in Q1; Q1 metrics included revenue of $336.6 million (reported +2% y/y; would have been low double‑digit growth absent the IRA), gross profit $76.0 million (+19% y/y; +14% excl. $3M benefit) with gross margin 22.7% (22.0% excl.), adjusted EBITDA $29.8 million (+27% y/y; +14% excl.) and an adjusted EBITDA margin of 8.8% (8.0% excl.), adjusted EPS $0.29, total residents ~207,000 (+10% y/y), script volumes +10%, cash $65 million, effective tax rate 26%, Q1 stock‑based comp ~$1.9 million (expect ~$3.0M/quarter going forward), acquisitions compressing consolidated margins by ~80 basis points, a nondilutive secondary of 6.9 million shares at $31, and management noted a temporary working‑capital impact from the IRA (≈50% of the quarter’s working‑capital use) plus potential headwinds from fuel (a few million dollars annually) and modestly higher labor as they scale.Guardian Pharmacy Services, Inc. Class A Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
83
Very Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.46B | 1.45B | 1.23B | 1.05B | 908.91M | 792.07M |
| Gross Profit | 304.68M | 292.72M | 244.37M | 208.31M | 185.87M | 161.26M |
| EBITDA | 101.53M | 96.42M | -43.43M | 58.81M | 68.15M | 46.49M |
| Net Income | 53.07M | 49.22M | -87.29M | 23.90M | 35.42M | 16.31M |
Balance Sheet | ||||||
| Total Assets | 426.94M | 412.66M | 320.81M | 271.17M | 256.11M | 235.85M |
| Cash, Cash Equivalents and Short-Term Investments | 64.89M | 65.62M | 4.66M | 752.00K | 607.00K | 15.01M |
| Total Debt | 36.88M | 37.14M | 37.33M | 69.15M | 62.98M | 55.04M |
| Total Liabilities | 194.52M | 194.73M | 170.83M | 211.31M | 180.18M | 182.53M |
| Stockholders Equity | 220.89M | 205.76M | 142.67M | 28.21M | 42.73M | 23.93M |
Cash Flow | ||||||
| Free Cash Flow | 70.01M | 80.71M | 41.59M | 56.26M | 31.75M | 49.22M |
| Operating Cash Flow | 88.77M | 100.29M | 57.96M | 70.82M | 48.52M | 58.50M |
| Investing Cash Flow | -31.35M | -32.26M | -30.41M | -13.44M | -17.90M | -13.15M |
| Financing Cash Flow | -6.52M | -7.07M | -23.64M | -57.23M | -45.03M | -36.79M |
Guardian Pharmacy Services, Inc. Class A Technical Analysis
Positive
37.54
Price Trends
36.55
Negative
34.13
Positive
30.61
Positive
Market Momentum
-0.23
Positive
48.52
Neutral
73.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRDN, the sentiment is Positive. The current price of 37.54 is above the 20-day moving average (MA) of 36.62, above the 50-day MA of 36.55, and above the 200-day MA of 30.61, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 73.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRDN.
Guardian Pharmacy Services, Inc. Class A Risk Analysis
Guardian Pharmacy Services, Inc. Class A disclosed 42 risk factors in its most recent earnings report. Guardian Pharmacy Services, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Guardian Pharmacy Services, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $2.38B | 44.84 | 27.21% | ― | 13.54% | ― | |
65 Neutral | $93.27B | 22.46 | -265.44% | 0.37% | 12.36% | 48.80% | |
63 Neutral | $46.66B | 31.11 | -55.72% | 0.98% | 12.80% | 2.04% | |
59 Neutral | $51.51B | 9.31 | 115.93% | 0.66% | 5.95% | 51.04% | |
56 Neutral | $8.34B | 19.36 | 11.86% | ― | 5.64% | 2.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GRDN
Guardian Pharmacy Services, Inc. Class A
37.63
15.57
70.58%
COR
Cencora
264.75
-24.43
-8.45%
CAH
Cardinal Health
199.23
47.63
31.42%
HSIC
Henry Schein
73.23
1.15
1.60%
MCK
McKesson
754.68
38.78
5.42%
Guardian Pharmacy Services, Inc. Class A Corporate Events
Executive/Board ChangesShareholder Meetings
Guardian Pharmacy Stockholders Back Directors, Pay and Auditor
Positive
May 7, 2026
On May 5, 2026, Guardian Pharmacy Services, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Class II directors John Ackerman and Randall Lewis to the board to serve until the 2029 annual meeting and the election of th...
Stock BuybackDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Guardian Pharmacy Services Ends Controlled Company Status on NYSE
Positive
Mar 23, 2026
On March 18, 2026, Guardian Pharmacy Services entered into stock purchase agreements with certain Class A shareholders, enabling the company to repurchase up to 1,833,344 shares in private transactions at prices tied to future underwritten offerin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.